Journals / Viral Hepatitis Journal / 2016 / Cilt: 22 - Sayı: 1

Telbivudine-Related Myopathy: A Case Report

Telbivudin İlişkili Miyopati: Bir Olgu Sunumu

Pages
45–46
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To detect this adverse event, monitoring of serum creatine kinase level and recognition of myopathic signs and symptoms are necessary.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Telbivudine has potent antiviral activity against hepatitis B virus.
📊
Key Findings & Data:Although there are several reports concerning the safety profile of telbivudine, most adverse events are described as mild and transient in nature.
💡
Conclusion & Impact:To detect this adverse event, monitoring of serum creatine kinase level and recognition of myopathic signs and symptoms are necessary.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Telbivudine has potent antiviral activity against hepatitis B virus. Although there are several reports concerning the safety profile of telbivudine, most adverse events are described as mild and transient in nature. In this paper, we report a case of reversible telbivudineinduced myopathy. To detect this adverse event, monitoring of serum creatine kinase level and recognition of myopathic signs and symptoms are necessary.

Özet

Telbivudin hepatit B virüsüne karşı güçlü bir antiviral etkinliğe sahiptir. Telbivudinin güvenlik profili ile ilgili birçok rapor olmasına rağmen, çoğu yan etkinin ılımlı ve geçici özellikleri tanımlanmıştır. Bu yazıda telbivudine bağlı geri dönüşümlü bir miyopati olgusu bildirilmiştir. Bu yan etkiyi saptamak için, serum kreatin kinaz düzeyinin izlenmesi ve miyopatik belirti ve bulguların tanınması gereklidir.

🔖

Cite This Article

AY, B., ÖZDEMİR, E., ÜNEL, N., ÇALIK, Ş., KARACA, B. (2016). Telbivudine-Related Myopathy: A Case Report. Viral Hepatitis Journal, Cilt: 22 - Sayı: 1, 45–46. https://ajindex.com/articles/332807

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. World health organization. Hepatitis B. Fact sheet N 204 Updated July 2014. Available at: http://www.who.int/mediacentre/ factsheets/fs204/en/. Accessed: 1 October 2014
  2. Europian Association For The Liver. EASL Clinical Practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185
  3. Finsterer J, Ay L. Myotoxicity of telbivudine in pre-existing muscle damage. Virol J 2010;7:323
  4. Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV. Efficacy and safety of continuous 4-yeartelbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20:37-46
  5. Zhang XS, Jin R, Zhang SB, Tao ML. Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol. 2008;14:3549-3553
  6. Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat. 2011;18:892-896.